PARP have been proved to be a new target in cancer therapy in nearly a decade, and PARP inhibitors stand for a reinvented example of precision medicine as the first drugs targeting DNA damage response to have triumphantly entered the clinic (110, 111). This evidence concerns the gene PARP1 and cancer.